Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Freegold Intersects 2.72 g/t Au over 139.9 metres at Golden Summit (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Lyra Therapeutics Inc LYRA

Healthcare Biotechnology
Lyra Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on the development and commercialization of therapies for the localized treatment of patients with chronic rhinosinusitis (CRS). The Company has two investigational product candidates, LYR-210 and LYR-220, in late-stage development for CRS, a prevalent inflammatory disease of the paranasal sinuses that... see more

Recent & Breaking News (NDAQ:LYRA)

Lyra Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update

GlobeNewswire November 12, 2024

Lyra Therapeutics Fully Enrolls Pivotal Phase 3 ENLIGHTEN 2 Trial of LYR-210 for the Treatment of Chronic Rhinosinusitis

GlobeNewswire October 15, 2024

Lyra Therapeutics to Present Study Results for LYR-210 and LYR-220 in Two Presentations at the ARS and AAO-HNS Annual Meetings

GlobeNewswire September 27, 2024

Lyra Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update

GlobeNewswire August 14, 2024

Lyra Therapeutics Announces Cost-Cutting Measures to Preserve Capital

GlobeNewswire May 21, 2024

Lyra Therapeutics Reports Topline Results from Phase 3 ENLIGHTEN 1 Trial for LYR-210 in Chronic Rhinosinusitis

GlobeNewswire May 6, 2024

Lyra Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update

GlobeNewswire April 30, 2024

Lyra Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire April 26, 2024

Lyra Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

GlobeNewswire March 21, 2024

Lyra Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire March 1, 2024

Lyra Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update

GlobeNewswire November 7, 2023

Lyra Therapeutics to Participate in Upcoming Investor Conferences

GlobeNewswire November 7, 2023

Lyra Therapeutics Announces Appointment of Ronan O'Brien as Chief Legal Officer

GlobeNewswire October 16, 2023

Lyra Therapeutics Announces Positive Topline Results from BEACON Phase 2 Study of LYR-220 for the Treatment of Chronic Rhinosinusitis (CRS) in Patients with Prior Ethmoid Sinus Surgery

GlobeNewswire September 12, 2023

Lyra Therapeutics to Participate in Upcoming Investor Conferences

GlobeNewswire September 6, 2023

Lyra Therapeutics Fully Enrolls Pivotal Phase 3 ENLIGHTEN I Trial of LYR-210 for the Treatment of Chronic Rhinosinusitis

GlobeNewswire August 29, 2023

Lyra Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update

GlobeNewswire August 8, 2023

Lyra Therapeutics to Present at William Blair Virtual Biotechnology Conference

GlobeNewswire July 13, 2023

Lyra Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire June 2, 2023

Lyra Therapeutics to Present at Jefferies Healthcare Conference

GlobeNewswire June 2, 2023